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Abstract
Aims Myoglobin is a haem protein produced in skeletal muscles. Serum concentrations of myoglobin have been proposed as
a surrogate marker of muscle mass and function in both cachectic cancer patients and healthy non-cancer individuals. Creat-
inine, a metabolite of creatine phosphate, an energy store found in skeletal muscle, is produced at a constant rate from skel-
etal muscle. Urinary and plasma creatinine have been used in clinical practice as indicators of skeletal muscle mass in health
and disease. Our study aimed to test the hypothesis that plasma myoglobin and creatinine concentration could accurately pre-
dict skeletal muscle mass and aerobic capacity in colorectal cancer (CRC) patients and matched healthy controls and thereby
an indicative of aerobic performance.
Methods We recruited 47 patients with CRC and matching number of healthy volunteers for this study. All participants had
their body composition measured by dual-energy X-ray absorptiometry scan, aerobic capacity measured to anaerobic thresh-
old (AT) by cardiopulmonary exercise testing and ﬁlled in objective questionnaires to assess the qualitative functions. This
study was carried out in accordance with the Declaration of Helsinki, after approval by the local National Health Service
(NHS) Research Ethics Committee.
Results Age-matched groups had similar serum myoglobin and creatinine concentrations in spite of differences in their aer-
obic capacity. AT was signiﬁcantly lower in the CRC group compared with matched controls (1.18 ± 0.44 vs. 1.41 ± 0.71 L/min;
P< 0.01). AT had signiﬁcant correlation with lean muscle mass (LMM) among these groups, but myoglobin and creatinine had
poor correlation with LMM and AT.
Conclusions Serum myoglobin is a poor predictor of muscle mass, and serum myoglobin and creatinine concentrations do
not predict aerobic performance in CRC patients or healthy matched controls.
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Introduction
The most common gastrointestinal cancer, colorectal cancer
(CRC)1,2 accounts for almost 16 000 deaths in the UK per
annum,3 making it the country’s third most common cancer
and the second most common cause of cancer-related death.
Rare below the age of 50, the incidence of CRC rises exponen-
tially after 60 years.4 Therefore, most patients who have CRC
are elderly and often have signiﬁcant co-morbidities.
Optimization of peri-operative care, chemo-radiotherapy,
and operative techniques has resulted in improved survival
for patients undergoing CRC resection,5 with operative mor-
tality decreasing year on year and currently between 2.3
and 4.3%.6 Morbidity rates, however, remain high (approxi-
mately 24%), negatively impacting on hospital length of stay
(LoS), critical care dependency, and long-term outcomes.7,8
Identiﬁcation of those individuals at risk of complications
and increased LoS is important, not only in trying to reduce
morbidity but in risk stratiﬁcation, targeted post-surgical care,
and discharge planning. Current risk stratiﬁcation tools such
as the Physiological and Operative Severity Score for the
enUmeration of Mortality and morbidity commonly fail to
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accurately predict surgical morbidity, especially at extremes
of age and functional status9 and are only valid after operation
and not pre-operatively. Accurate pre-operative risk predic-
tion therefore remains a signiﬁcant clinical challenge.
One approach to the identiﬁcation of the high-risk surgical
patient that has shown promise is the evaluation of cardiore-
spiratory performance. Although estimation of exercise toler-
ance based on verbal history or static cardiac and pulmonary
functions is unreliable as a predictor of peri-operative perfor-
mance, cardiopulmonary exercise testing (CPET), used to
measure the capacity for oxygen delivery, has been identiﬁed
as a good predictor of mortality and morbidity following ma-
jor surgery.10–12 Unfortunately, CPET is not universally avail-
able and exposes the patient to a small risk of non-fatal
adverse event, of approximately one in 2000, dependent
upon pre-existing comorbidity.13,14
Similarly, skeletal muscle mass has also been shown to be
an important predictor of post-operative LoS and complica-
tions, serving as a prognostic factor for surgical outcome.15
The muscle wasting seen in cancer patients is most aggressive
in those with gastrointestinal solid tumours, where weight
loss is experienced by over half of patients.16,17 Indeed, up
to 60% of patients display some degree of muscle atrophy
and approximately a quarter lose 5% of their body weight
in the 6months before diagnosis.15,18,19 Previous research
has revealed a close correlation between aerobic perfor-
mance and muscle mass in health,20–22 and indicated that
pre-operative muscle loss may inﬂuence peri-operative out-
come, increasing mortality and morbidity in cancer patients
undergoing major gastrointestinal surgery.23,24 Furthermore,
surgery itself places metabolic demands upon the body,25
resulting in marked changes in body composition with further
losses of lean muscle mass (LMM) in already cachectic pa-
tients.26 However, muscle wasting is not easily recognized
pre-operatively by clinical examination and body weight
changes, as variations are frequently masked by oedema, as-
cites, or increased adiposity due to altered nutrition.
There is therefore a need for a clinically applicable marker
of muscle mass that can be easily acquired in the clinical en-
vironment pre-operatively, with predictive value for physical
performance, post-operative outcome, and risk stratiﬁcation,
before major intra-abdominal surgery in cancer patients. Two
metabolites of skeletal muscle, myoglobin and creatinine,
have previously been suggested as surrogate markers fulﬁll-
ing the aforementioned criteria.20,27–29
Myoglobin is a haem protein produced within skeletal
muscle, which binds oxygen and acts as the primary oxygen
delivery protein in skeletal muscle. It is also most prevalent
in Type 1 and 2a muscle ﬁbres,30 the ﬁbres intimately in-
volved in aerobic exercise performance.31 It has been pro-
posed as a surrogate marker of muscle mass and function in
cachectic cancer patients and healthy non-cancer individ-
uals.20,32,33 Creatinine a metabolite of creatine phosphate,
an energy store found in skeletal muscles, is produced at a
constant rate from skeletal muscles. Similarly, urinary and
plasma creatinine have been used in clinical practice as indi-
cators of skeletal muscle mass in health and disease.28,29
Using a prospective study design, this study aimed to test
the hypothesis that plasma myoglobin and creatinine concen-
tration could accurately predict skeletal muscle mass
[assessed by dual-energy X-ray absorptiometry (DXA)] and
aerobic capacity (measured by CPET) in CRC patients and
matched healthy controls and that these measures were, by
extension, indicative of aerobic performance.
Materials and methods
Subject characteristics and study protocol
The study was carried out in accordance with the Declaration
of Helsinki, after approval by the local NHS Research Ethics
Committee (REC 08/H0401/101). All subjects gave their writ-
ten, informed consent to participate in the study. Two groups
of subjects were recruited; one consisting of CRC patients
without distant metastasis on pre-operative staging and the
other consisting of healthy volunteers. Consecutive CRC pa-
tients eligible to be included were approached in a clinic to
be included in the study. The two groups were matched by
age, sex, and weight. Before commencing the study, all sub-
jects were screened for metabolic, respiratory, or cardiovas-
cular disorders using a medical questionnaire, physical
examination, and resting ECG. Exclusion criteria for both
groups were the following: neoadjuvant chemoradiotherapy,
strenuous exercise, intramuscular injection in the 48 h pre-
ceding assessment, known neuropathy or myopathy,
wheelchair-bound individuals or those with mobility prob-
lems and pregnancy. Subjects were also required to have nor-
mal blood chemistry results and to have blood pressure
within normal limits (BP< 140/90). Individuals with well-
controlled hypertension were not excluded from the study.
All subjects were studied on one occasion; for the CRC pa-
tients, this was pre-operatively within 4weeks of surgery.
A required sample size of 92 subjects was estimated based
on previously published work,41 assuming a variation of 0.12
with a power of 80% and signiﬁcance level of 5% (nQuery Ad-
visor Version 5, Statistical Solutions Ltd, Ireland). Previous ex-
perience in our unit yielded a recruitment rate of 25% of total
eligible patients. Therefore, we aimed to recruit 46 CRC pa-
tients in 18months concurrently with matched volunteer
controls, making a total of 92 recruits. Potential CRC subjects
were identiﬁed in the colorectal multidisciplinary team meet-
ing after a diagnosis of CRC had been made and absence of
distant metastasis conﬁrmed. Healthy volunteers were re-
cruited through advertisements placed in the surgical outpa-
tients department and throughout the Derby Hospitals NHS
Foundation Trust and University of Nottingham.
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Measurement of body composition
Subjects were instructed to refrain from unaccustomed exer-
cise for 48 h and from alcohol and caffeine for 24 h before
study days. All subjects fasted from 9p.m. the night before,
with water ad libitum. Studies began at 9 a.m. with measure-
ment of body weight, height, and body composition, mea-
sured by DXA (Lunar Prodigy II, GE Medical Systems).34 DXA
is well accepted, precise, and reproducible (±5%) in the mea-
surement of whole body and regional (e.g. limb) muscle mass.
Although not as precise or sensitive as computed tomography
(CT) or magnetic resonance imaging (MRI), DXA is much
cheaper and more accessible than CT or MRI and avoids rela-
tively high doses of ionizing radiation in the case of CT.35–37
DXA also compares well with other recognized methods of
body composition measurement such as neutron activation
and total body K analysis.28,38–42
Measurement of anaerobic threshold
After the DXA scan, CPET was performed using a Lode Corival
cycle ergometer (Lode Corival, Lode, Groningen, Netherlands)
and an online gas analysis system (ZAN 680, nSpire Health,
Longmont, CO, USA) using a standard protocol while super-
vised by a medically qualiﬁed doctor. In brief, after equipment
calibration and explanation of the study protocol, subjects
were seated on the ergometer, and the position was adjusted
to ﬁt. Subjects were then ﬁtted with a face-mask from which
inspired and expired gases were sampled during exercise. In
order to ensure accurate gas analysis, masks were checked
for any leaks prior to exercise. Following this, participants
sat at rest on the bike for 2min, then, following a 2min
warm-up period, cycling workload was increased in a ramped
step-wise manner by 20W/min (4W12 s1), with individuals
encouraged to maintain a cadence of 60–70 rpm. Subjects
were verbally encouraged to exercise to 85% or more of
predicted maximal heart rate and to a respiratory exchange
ratio (VCO2/VO2) above 1.1. Tests were deemed complete
once the attending clinician was sure that AT had been
achieved. A 12-lead ECG was measured continuously
throughout the test (CardioCollect12S, DelMar Reynolds)
and non-invasive blood pressure collected every 2min. Tests
were terminated in the event of severe dyspnoea, systolic
blood pressure reduction>20mmHg, signiﬁcant arrhythmias,
ischaemic ECG changes, angina pain, exercise blood pressure
>250mmHg systolic or 115mmHg diastolic, or inability to
maintain a cycling cadence of 60–70 rpm. On completion of
the study, AT was calculated from the data recorded, by
two independent trained observers blinded to participant
group, using the dual criteria of the V-slope and ventilatory
equivalents methods12 from graphs generated using ZAN
680 software and determined as the mean of these two
values.
Venous blood
For collection of serum, a sample of whole venous blood was
drawn into a BD vacutainer serum separator tube (Becton,
Dickinson and Company, Franklin Lakes, New Jersey, USA)
and immediately centrifuged at 3000 rpm for 10min at 4°C
to separate the serum fraction of the sample. Serum was
then removed and stored at 80°C in for analysis (within
6months). In addition, further bloods were also drawn from
volunteer and patient groups, including for routine pre-
operative assessment in the patient group. These samples
were analysed for plasma creatinine and full blood count
using standard automated laboratory techniques within the
Derby Hospitals NHS Trust.
Myoglobin enzyme-linked immunosorbent assay
Serum myoglobin was measured using a human myoglobin
enzyme-linked immunosorbent assay immunoassay kit (DRG
International Inc., Springﬁeld, NJ, USA) according to the man-
ufacturer’s instructions, by an individual unaware of partici-
pant group. In brief, after slow thawing, serum samples
were diluted 10-fold with sample diluent before use. Twenty
microlitres of diluted serum sample or control, of known
myoglobin concentration, were dispensed into the appropri-
ate wells on a pre-coated 96-well plate before 200mL of
enzyme conjugate reagent was added into each well. Plates
were mixed thoroughly for 30 s on a plate-shaker (Multiskan
Ascent plate reader, Ascent software V 2.6, Thermo Scientiﬁc,
Waltham, MA, USA) and incubated at room temperature
(18–25°C) for 45min. The content of the wells was then re-
moved and the plate washed ﬁve times with de-ionized water.
During each wash, any residual water was removed by striking
the wells sharply onto paper towel. After the wash step,
100μL of tetramethyl-benzidine reagent was added to each
well, and the plate was gently mixed for 5 s. Plates were then
incubated at room temperature for 20min, after which the re-
action was stopped by the addition of 100μL of stop-solution
to each well. Following a gentle 30 s mix, absorbance was read
within 15min at 450 nm using a microtitre plate reader.
Statistical analysis
All statistical analyses were carried out using Statistical Pack-
age for the Social Sciences (SPSS v20; IBM Armonk, NY, USA).
The signiﬁcance level was set at P< 0.05. Descriptive data are
presented as mean ± standard deviation (SD) or median with
range. Data were tested for normal distribution using the
Shapiro–Wilk test and compared using the Student’s t-test
or Mann–Whitney U-test as appropriate. Correlations were
explored using Pearson’s R correlation, with results expressed
as a coefﬁcient of determination (r2).
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Results
Body composition
In total, 94 individuals were recruited to the study, 47 pa-
tients with CRC awaiting surgical resection and 47 matched
controls. All individuals reached AT as deﬁned by the study
protocol with no study drop-outs. Patients with CRC were
matched for age and gender with healthy controls (age:
65.04 ± 7.7 vs. 65.8 ± 7.3 years; P = 0.58; gender (M:F): 33:14
vs. 27:20; P = 0.28 (Table 1). Body mass index (BMI) was
28.46 ± 0.62 kg/m2 in the CRC patients and 26.92 ± 0.5 kg/m2
in the healthy controls (P = 0.06). There was no signiﬁcant
difference in LMM between CRC patients and controls
(50 530 ± 1575 vs. 47 320 ± 1373 g; P = 0.13). Despite similar
LMM, CRC patients were signiﬁcantly heavier than controls
(81.64 ± 2.19 vs. 74.94 ± 1.8 kg; P = 0.02). None of the CRC
patients had distant metastases on pre-operative cross-
sectional imaging (Table 2) or at operation. There was no
signiﬁcant difference between groups in terms of co-morbid
conditions.
Serum analytes
Serum myoglobin levels were within the normal range in
both groups, and there was no signiﬁcant difference be-
tween CRC patients and controls (53.64 ± 9.95 vs. 44.03
± 4.45 ng/dL; P = 0.38). Serum creatinine levels were also
within the normal range in both groups, and again there
was no signiﬁcant difference between groups (83.51 ± 2.82
vs. 80.08 ± 2.75 nmol/L; P = 0.39). There was a statistically sig-
niﬁcant correlation between creatinine and LMM in both
groups (control: r2 = 0.22, P< 0.01; CRC: r2 = 0.14, P = 0.01)
and in all participants when analysed together (r2 = 0.18,
P< 0.0001). There was not a signiﬁcant correlation between
LMM and myoglobin in either group or when all study partic-
ipants were analysed as a whole (control: r2 = 0.03, P = 0.3;
CRC: r2 = 0.04, P = 0.19; all participants: r2 = 0.04, P = 0.07)
(Figure 1).
Cardio-pulmonary exercise testing
Anaerobic threshold was signiﬁcantly lower in the CRC
group compared with matched controls (1.18 ± 0.44 vs.
1.41 ± 0.71 L/min; P< 0.01). In both CRC and control groups,
AT showed a strong correlation with LMM (CRC: r2 = 0.38,
P< 0.0001; control: r2 = 0.41, P< 0.0001; all participants:
r2 = 0.26, P< 0.0001) but a weaker correlation with body
weight (CRC: r2 = 0.20, P< 0.01; control: r2 = 0.19, P = 0.01).
There was no signiﬁcant or clinically meaningful correlation
between either creatinine or myoglobin and AT in either
the control group (creatinine: r2 = 0.03, P = 0.34; myoglobin:
r2< 0.01, P = 0.99) or the CRC patients (creatinine:
r2 = 0.11, P = 0.04; myoglobin: r2 = 0.05, P = 0.16). Correlation
Table 1 Table of participant demographics and characteristics
Characteristic Control CRC P value
n (male:female) 47 (27:20) 47 (33:14) 0.28
Age (years) 65.8± 7.3 65.04±7.7 0.58
Height (cm) 166.8±1.35 168.6± 1.34 0.36
Weight (kg) 74.94±1.87 81.64± 2.19 0.02
BMI (kg/m2) 26.92±0.51 28.46± 0.62 0.06
AT (L/min) 1.41±0.71 1.18± 0.44 <0.01
LMM (g) 47320±1373 50530± 1575 0.13
Hb (g/L) 13.1± 0.3 12.6± 0.4 0.32
Myoglobin (μg/L) 44.03±4.45 53.64± 9.95 0.38
Creatinine (mg/dL) 80.08±2.75 83.51± 2.82 0.39
Co-morbid conditions
Respiratory 9 10 0.24
Cardiac 15 15 1.0
Renal and diabetes
mellitus
4 6 0.74
Other (including
controlled
hypertension)
13 9 0.47
AT, anaerobic threshold; BMI, body mass index; CRC, colorectal
cancer; LMM, lean muscle mass.
Data presented as mean and standard deviation, with data
analysed via Student’s t-test, Mann–Whitney U-test, or Fisher’s
exact test as appropriate.
Table 2 Tumour node metastases staging for colorectal cancer study participants
TNM stage Description n
Tis N0 M0 Tis: Tumour conﬁned to mucosa; cancer-in-situ 2
T1N0M0 T1: Tumour invades submucosa 2
T2N0M0 T2: Tumour invades muscularis propria 12
T3N0M0 T3: Tumour invades subserosa or beyond (without other organs involved) 16
T4N0M0 T4: Tumour invades adjacent organs or perforates the visceral peritoneum 3
T1-2N1M0 N1: metastasis to one to three regional lymph nodes. T1 or T2. 3
T3-4N1M0 N1: metastasis to one to three regional lymph nodes. T3 or T4. 8
any T, N2 M0 N2: metastasis to four or more regional lymph nodes. Any T. 1
any T, any N, M1 M1: distant metastases present. Any T, any N. 0
TNM, tumour node metastases.
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between the independent observers calculation of AT was
high (r = 0.79) (Figure 2).
Discussion
The results of this study demonstrate that plasma myoglobin
is a poor predictor of muscle mass, and that plasma myoglo-
bin and creatinine concentrations do not predict aerobic per-
formance in CRC patients or healthy matched controls.
Conversely, weight was strongly predictive of LMM in these
two populations. Moreover, both weight and LMM predict
aerobic performance, with LMM closely related to aerobic
performance in both health and CRC.
Despite previous smaller studies in disparate groups of
cancers suggesting that myoglobin can be used as a surro-
gate predictive marker of functionally relevant muscle
mass and aerobic performance in health and cancer
states,20 using a larger cohort and homogeneous cancer lo-
cation, we found no clear relationship between plasma
myoglobin concentration and LMM or aerobic performance
(CPET assessed AT) in healthy individuals or CRC patients.
This is despite myoglobin being most highly expressed in
the muscle ﬁbres closely associated with aerobic
performance.43
In tandem with previous studies, we do, however, ﬁnd a
signiﬁcant, albeit weak, correlation between plasma creati-
nine concentration and LMM. This relationship was present
in both healthy volunteers and individuals suffering from
CRC, mirroring previous studies in the literature which report
creatinine’s ability to predict LMM in healthy individuals and
those suffering from chronic renal disease.29,44 Plasma
creatinine was, however, inconsistently related to aerobic
performance, showing no correlation with aerobic perfor-
mance in health and only a weak relationship in CRC, indicat-
ing its limited utility as a marker of diminished functional
performance.
This study does, however, show that the simple measure of
DXA-assessed LMM is strongly predictive of AT in both
healthy volunteers and patients with non-disseminated CRC,
demonstrating a coefﬁcient of determination of approxi-
mately 40%. This close relationship suggests that routine
quantiﬁcation of LMM via DXA could help recognize those pa-
tients with a diminished aerobic capacity prior to surgery and
therefore identify those who may beneﬁt from more rigorous
pre-operative testing.
We accept that there are a number of limitations in this
study. Firstly, individuals were not exercised to VO2 max but
to AT. This was based on a pragmatic clinical decision that
many patients may ﬁnd exercising to maximal effort
distressing and/or unachievable. In light of the literature
supporting the use of AT as an exercise end-point in the
pre-operative patient45 we do not think this decision nega-
tively impacts upon our ﬁndings. Secondly, the mean AT
threshold for the CRC patients studied in this present inves-
tigation was 14.4mL/kg/min, and above the level generally
considered to elicit concern during pre-operative assess-
ment.46 There is therefore clearly a need for further work
to either conﬁrm or refute the association between LMM
and aerobic performance at lower values of AT. We have
no reason to believe, given the clear relationship between
aerobic performance and LMM that this relationship would
not be maintained at lower anaerobic thresholds. In addi-
tion, individuals were not exercised through individually tai-
lored protocols, but at a ﬁxed 20W/min ramp, introducing
the possibility of error when calculating AT for those at the
Figure 1 Plots of (A) weight (kg) vs. lean muscle mass (g), (B) creatinine
(mg/dL) vs. lean muscle mass (g), and (C) myoglobin (μg/dL) vs. lean
muscle mass (g). Open circles represent control group, while closed cir-
cles represent colorectal cancer patients (CRC).
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extremes of ﬁtness levels. Finally, both our CRC patients
and healthy controls had BMI values within the normal
range for a pre-operative population. Results of this study
might not extend to the sarcopenic and/or obese patient.
Conclusion
This study shows a relationship between LMM and aerobic
performance in healthy individuals that is preserved in non-
disseminated CRC, and refutes the suggestion that plasma
myoglobin or creatinine may be a clinically useful marker of
functional muscle mass, and by extension aerobic perfor-
mance, in the pre-operative CRC patient or indeed healthy
volunteers. Measurement of LMM is an effective surrogate
for aerobic performance in health and non-disseminated
CRC and could be used pre-operatively to identify individuals
who would beneﬁt from a more extensive pre-operative
assessment.
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